Sankala Group
XBI icon

Sankala Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sankala Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.8K Hold
150
– – 0.02% 301
2026
Q2 		$24K Hold
150
– – 0.02% 319
2026
Q1 		$18.3K Hold
150
– – 0.01% 321
2025
Q4 		$19.1K Buy
+150
New +$17.2K 0.02% 321

Other funds holding XBI

Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return
Natixis
Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return
Employees Retirement System of Texas
Employees Retirement System of Texas Austin, Texas $12.2B AUM 27.55% 1-Year Est. Return
Investure LLC
Investure LLC Charlottesville, Virginia $1.83B AUM 14.32% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Sankala Group's XBI Position: Q3 2026 in Review

Sankala Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2026 at 150 shares worth $23.8K. The position accounts for 0.02% of the portfolio, ranked #301.

Sankala Group first reported a position in XBI in Q4 2025 and has held it in 4 quarters since. The position peaked at $24K in Q2 2026. 604 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Sankala Group held 150 shares of State Street SPDR S&P Biotech ETF worth $23.8K as of Q3 2026.
  • Sankala Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2026.
  • State Street SPDR S&P Biotech ETF made up 0.02% of Sankala Group's portfolio in Q3 2026, its #301 holding.
  • Sankala Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 4 quarters since.
  • Sankala Group's State Street SPDR S&P Biotech ETF position peaked at $24K in Q2 2026.
  • 604 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.